Kitov Pharmaceuticals Holdings Ltd., of Tel Aviv, Israel, said it closed its public offering of about 2.4 million class A units, with each unit consisting of one American depositary share (ADS) and a warrant to purchase one ADS, as well as about 1.2 million class B units, with each consisting of a nonlisted, pre-funded warrant to purchase one ADS and a listed warrant.